Frontiers in Pharmacology (Aug 2021)

Enhanced Bioavailability of Dihydrotanshinone I–Bovine Serum Albumin Nanoparticles for Stroke Therapy

  • Yanru Ren,
  • Yicheng Feng,
  • Kunyao Xu,
  • Saisai Yue,
  • Tiantian Yang,
  • Kaili Nie,
  • Man Xu,
  • Haijun Xu,
  • Xin Xiong,
  • Fabian Körte,
  • Mike Barbeck,
  • Peisen Zhang,
  • Luo Liu

DOI
https://doi.org/10.3389/fphar.2021.721988
Journal volume & issue
Vol. 12

Abstract

Read online

Dihydrotanshinone I (DHT) is a natural component in Salvia miltiorrhiza and has been widely researched for its multiple bioactivities. However, poor solubility and biocompatibility of DHT limit its desirable application for clinical purposes. Herein, DHT was encapsulated with bovine serum albumin (BSA) to enhance bioavailability. Compared to free DHT, DHT–BSA NPs (nanoparticles) showed an improved solubility in normal saline and increased protection against hydrogen peroxide–induced oxidative damage in PC12 cells. In addition, DHT–BSA NPs administered by intravenous injection displayed a significant efficacy in the middle cerebral artery occlusion/reperfusion models, without any impact on the cerebral blood flow. In summary, DHT–BSA NPs show an enhanced bioavailability compared with free DHT and a successful penetration into the central nervous system for stroke therapy, demonstrating their application potential in cardio–cerebrovascular diseases.

Keywords